Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
First-time investors should be aware of common mistakes that can lead to losses. Here’s what not to do for a successful start.
28,109 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
GLAD faces a delicate turning point as the Fed freezes rates, pressuring yields on its floating-rate loans while port...
Senator Elizabeth Warren escalates her opposition to the OCCs handling of crypto trust charters, arguing the agency h...
A New York-based startup unveiled an autonomous, AI-powered offensive security platform, raising $37 million from Lig...
Markets confront a rebalanced risk outlook as Iran signals it may push for nuclear concessions to survive. Investors ...
PepsiCo trims snack prices in North America to spur demand, but the pause in regional growth keeps investors focused ...
New York Governor Hochul’s decision to pause autonomous for-hire vehicle expansion outside NYC hits Waymo and Tesla’s...
Solmate plans a reverse stock split to fund a Solana-focused hub in the UAE, part of a broader pivot that includes ex...
DoorDash sits near 52-week levels after a tough quarter that piled up costs from Deliveroo and grocery pushes. Yet Wa...
Home Depot says customers remain healthy, but big-ticket remodeling and discretionary purchases are cooling in pocket...
A new release from Anthropic is triggering a global debate over hidden safeguards. Critics say Claude Fable 5 quietly...
Spot Bitcoin ETFs posted a seventh straight week of net outflows, with about $1.8 billion pulled in the week ending J...